ABSTRACT
“Aspirin resistance” and “aspirin nonresponsiveness” are terms used both to describe both the failure of aspirin to protect subgroups of individuals from severe vascular events and to evoke an appropriate inhibition of platelet function. Several studies utilizing a broad range of platelet function tests have shown that some subgroups of individuals exhibit a reduced or completely missing antiplatelet response to aspirin. The clinical significance of aspirin nonresponsiveness for the prediction of clinical endpoints remains, however, to be determined. Thus far, only three prospective clinical trials have demonstrated a possible relationship between aspirin nonresponsiveness and subsequent vascular events. Most platelet function tests used in respective clinical studies cannot be reliably performed in clinical routine and are not interchangeable for monitoring antiplatelet treatment. There is a need for a simple and reliable assay for predicting the clinical efficacy of antiplatelet therapy. Recent data demonstrate that none of the currently developed assays, including the PFA-100 system, are presently able to accomplish these objectives.
KEYWORDS
Aspirin - aspirin nonresponsiveness - platelet function tests - predictive value
REFERENCES
-
1
Schrör K.
Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Semin Thromb Hemost.
1997;
23
349-356
-
2
Steering Committee of the Physicians’ Health Study Research Group .
Final report on the aspirin component of the ongoing Physicians’ Health Study.
N Engl J Med.
1989;
321
129-135
-
3
Antithrombotic Trialists’ Collaboration .
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
BMJ.
2002;
324
71-86
-
4
Patrono C, Coller B, Dalen J E et al..
Platelet active drugs. The relationships among dose, effectiveness, and side effects.
Chest.
2001;
119
39S-63S
-
5
Cambria-Kiely J A, Gandhi P J.
Aspirin resistance and genetic polymorphisms.
J Thromb Thrombolysis.
2002;
14
51-58
-
6
McKee S A, Sane D C, Deliagyris N.
Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance.
Thromb Haemost.
2002;
88
711-715
-
7
Howard P A.
Aspirin resistance.
Ann Pharmacother.
2002;
36
1620-1624
-
8
Halushka M K, Walker L P, Halushka P V.
Genetic variation in cyclooxygenase-1: effects on response to aspirin.
Clin Pharmacol Ther.
2003;
73
122-130
-
9
Grotemeyer K H, Scharafinski H W, Husstedt I W.
Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients.
Thromb Res.
1993;
71
397-403
-
10
Mueller M R, Salat A, Stangl P et al..
Variable platelet response to low-dose ASA and the link of limb deterioration in patients submitted to peripheral arterial angioplasty.
Thromb Haemost.
1997;
78
1003-1007
-
11
Gum P A, Kottke-Marchant K, Welsh P A, White J, Topol E J.
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
J Am Coll Cardiol.
2003;
41
961-965
-
12
Born G VR.
Aggregation of blood platelets by adenosine diphosphate and its reversal.
Nature.
1962;
194
927-929
-
13
Born G V, Dearnley R, Foulks J G, Sharp D E.
Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors.
J Physiol.
1978;
280
193-212
-
14
Cardinal D C, Flower R J.
The electronic aggregometer: a novel device for assessing platelet behaviour in blood.
J Pharmacol Methods.
1980;
3
135-158
-
15
Wu K K, Hoak J C.
A new method for quantitative detection of platelet aggregates in patients with arterial insufficiency.
Lancet.
1974;
22
924-926
-
16
Grotemeyer K H.
The platelet reactivity test. A useful by-product of the blood sampling procedure?.
Thromb Res.
1991;
61
423-431
-
17
Hurlen M, Seljeflot I, Arnesen H.
The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction.
Scand Cardiovasc J.
1998;
32
233-237
-
18
Kratzer M A, Born G V.
Simulation of primary haemostasis in vitro.
Haemostasis.
1985;
15
357-362
-
19
Gum P A, Kottke-Marchant K, Poggio E D et al..
Profile and prevalence of aspirin resistance in patients with cardiovascular disease.
Am J Cardiol.
2001;
88
230-235
-
20
Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S.
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Circulation.
2002;
105
1650-1655
-
21
Weber A A, Przytulski B, Schanz A, Hohlfeld T, Schör K.
Towards a definition of aspirin resistance: a typological approach.
Platelets.
2002;
13
37-40
-
22
Breddin K, Ziemen M, Bauer O et al..
Time and temperature dependent changes of ADP- and collagen-induced and “spontaneous” aggregation.
Thromb Res.
1980;
19
621-638
-
23
Nicholson N S, Panzer-Knodle S G, Haas N F et al..
Assessment of platelet function assays.
Am Heart J.
1998;
135
S170-S178
-
24
Sane D C, McKee S A, Malinin A I, Serebruany V L.
Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin.
Am J Cardiol.
2002;
90
893-895
-
25
Helgason C M, Tortorice K L, Winkler S R et al..
Aspirin response and failure in cerebral infarction.
Stroke.
1993;
24
345-350
-
26
Helgason C M, Bolin K M, Hoff J A et al..
Development of aspirin resistance in persons with previous ischemic stroke.
Stroke.
1994;
25
2331-2336
-
27
Weksler B B, Kent J L, Rudolph D, Scherer P B, Levy D E.
Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia.
Stroke.
1985;
16
5-9
-
28
Berglund U, Wallentin L.
Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease.
Eur Heart J.
1991;
12
428-433
-
29
Kundu S K, Heilmann E J, Sio R, Garcia C, Ostgaard R A.
Description of an in vitro platelet function analyzer, PFA-100.
Semin Thromb Hemost.
1995;
21
106-112
-
30
Jilma B.
Platelet function analyzer (PFA-100): a tool to quantify congenital and acquired platelet dysfunction.
J Lab Clin Med.
2001;
138
152-163
-
31
Mammen E F, Comp P C, Gosselin R et al..
PFA-100 system: a new method for assessment of platelet dysfunction.
Semin Thromb Hemost.
1998;
24
195-202
-
32
Fressinaud E, Veyradier A, Truchoud I et al..
Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.
Blood.
1998;
91
1325-1331
-
33
Böck M, de Haan J, Beck K H et al..
Standardization of the PFA-100 platelet function test in 105 mmol/L buffered citrate: effect of gender, smoking, and oral contraceptives.
Br J Haematol.
1999;
106
898-904
-
34
Macchi L, Christiaens L, Brabant S et al..
Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate.
Thromb Res.
2002;
107
45-49
-
35
ten Berg J M, Gerritsen W BM, Haas F JLM, Kelder H C, Verheugt F W, Plokker H W.
High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention.
Thromb Res.
2002;
105
385-390
-
36
Hézard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P.
PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?.
Thromb Res.
2002;
108
43-47
-
37
Harrison P.
Progress in the assessment of platelet function.
Br J Haematol.
2000;
111
733-744
-
38
Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W.
Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.
Thromb Haemost.
2000;
83
316-321
-
39
Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H.
Aspirin non-responder status in patients with recurrent cerebral ischemic attacks.
J Neurol.
2003;
250
63-66
-
40
Grotemeyer K H.
Effects of acetylsalicylic acid in stroke patients-evidence of nonresponders in a subpopulation of treated patients.
Thromb Res.
1991;
63
587-593
-
41
FitzGerald G A, Pedersen A K, Patrono C.
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
Circulation.
1983;
67
1174-1177
-
42
Granström E.
Methodology in prostaglandin and thromboxane assay.
Prog Lipid Res.
1986;
25
119-127
Peter HellsternM.D.
Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital
D-67063 Ludwigshafen, Germany
Email: peterhellstern@medicusnet.de
